Outcomes of Turkish National Breast Cancer Registry.
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: The aim of this registry was to collect demographic, diagnostic, treatment, and outcome information about Turkish patients with breast cancer (BC). Methods: It was designed as a multicenter, cross-sectional, non-interventional study conducted on new and previously diagnosed BC cases applied to 28 medical oncology outpatient clinics between 2012 and 2015. A total of 16841 male (n = 153) and female (n = 16688) patients > 18 years were included. Results: Mean age of BC patients was 52.0±11.5 years. Among women, 53.7% were postmenopausal, and 24.4% were receiving hormone replacement (HRT) and/or oral contraceptive therapies (OCT). At time of diagnosis, 18.2% of patients presented with Stage 1, 48.5% with Stage 2, 25.5% with Stage 3, and 7.9% with Stage 4 BC. In 79,8% of the patients histopathology was invasive ductal carcinoma. Estrogen (ER) and progesterone receptors (PR) were positive in 74.7%, and 69.4% of patients, respectively. Diagnostic immunohistochemistry (IHC) was performed in 90.4% of patients. HER2+ was found in 30.2% of patients. HER2+ was observed in 27.6% Stage I, 27.6% Stage II, 36.2% Stage III, and in 41.7% Stage 4 BC. ER and PR positivity were 62.4% and 56.4% among HER2+ patients, respectively. Neoadjuvant therapy was administered in 10.6% and adjuvant therapy was administered in 73.2% of patients. Between 2010 and 2015, trastuzumab was administered in 68.3% of adjuvant (n = 1959), and 7.5% of neoadjuvant (n = 215) HER2+ patients. Conclusions: BC is a major health concern. Majority of the patients are diagnosed in stage 2 or 3, therefore screening should be improved to diagnose patients at earlier stages. In HER2 positive patients, neoadjuvant trastuzumab usage is limited despite its known advantages.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Outcomes of Turkish National Breast Cancer Registry.
- Date Crossref
- 20/05/2017
- Éditeur
- American Society of Clinical Oncology (ASCO)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hacettepe University pays non établi dans la noticeUniversité ou école supérieure
-
Istanbul Medeniyet University pays non établi dans la noticeUniversité ou école supérieure
-
Ankara Numune Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Kayseri Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Trakya University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Inonu University pays non établi dans la noticeUniversité ou école supérieure
-
Dicle University pays non établi dans la noticeUniversité ou école supérieure
-
Dokuz Eylül University pays non établi dans la noticeUniversité ou école supérieure
-
Karadeniz Technical University pays non établi dans la noticeUniversité ou école supérieure
-
Istanbul University-Cerrahpaşa pays non établi dans la noticeUniversité ou école supérieure
-
Ege University pays non établi dans la noticeUniversité ou école supérieure
-
Başkent University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
Hacettepe University, Istanbul Medeniyet University et Ankara Numune Eğitim ve Araştırma Hastanesi, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.